Added to YB: 2024-12-04
Pitch date: 2024-12-02
TMDX [bullish]
TransMedics Group, Inc.
-0.73%
current return
Author Info
No bio for this author
Company Info
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
Market Cap
$3.3B
Pitch Price
$77.08
Price Target
200.00 (+161%)
Dividend
N/A
EV/EBITDA
29.64
P/E
23.61
EV/Sales
5.51
Sector
Health Care Equipment and Supplies
Category
turnaround
Why $TMDX Could Be 2025’s Breakout Stock
TMDX: Revolutionary organ transplant tech, 50% dip on Q3 miss (rev $108M, EPS $0.12). Temporary aviation/logistics issues squeezed margins. Long-term outlook strong: 10K transplants by 2028 ($1B rev), 20% EBITDA margins. No direct competitors. $200 price target.
Read full article (2 min)